학술논문
Olaparib-Induced Immune-Mediated Liver Injury
Document Type
Academic Journal
Author
Source
ACG Case Reports Journal. Jan 01, 2022 9(1):e00735-e00735
Subject
Language
English
ISSN
2326-3253
Abstract
ABSTRACT: Immune-mediated drug-induced liver injury can be triggered by multiple classes of medications including immunotherapies. Olaparib is a first-in-class oral inhibitor of poly (adenosine diphosphate-ribose) polymerase (an enzyme involved in DNA replication and repair) that is approved as maintenance treatment in platinum-sensitive, epithelial ovarian, tubal, or primary peritoneal cancers with breast cancer 1/2 mutation. We report the first case in the United States of an acute and severe liver injury with associated jaundice and liver synthetic dysfunction secondary to olaparib. The liver injury was resolved with drug cessation and treatment with prednisone taper.